Repression of RUNX1/ETO by LNPs extended the survival of leukaemic mice compared to control LNPs which is in line with previous work showing that targeting leukaemic fusion genes by siRNA-LNPs has the potential to reduce leukaemic burden and to provide survival benefits in AML and CML xenograft models [48, 52]. This evidence concerns the gene RUNX1T1 and chronic myelogenous leukemia, BCR-ABL1 positive.